Screening for ovarian cancer US preventive services task force recommendation statement

JAMA - Journal of the American Medical Association

Volumn 319, Issue 6, 2018, Pages 588-594

  Grossman, David C ^a   Curry, Susan J ^b   Owens, Douglas K ^c,d   Barry, Michael J ^e   Davidson, Karina W ^f   Doubeni, Chyke A ^g   Epling, John W ^h   Kemper, Alex R ⁱ   Krist, Alex H ^j,k   Kurth, Ann E ^l   Landefeld, C Seth ^m   Mangione, Carol M ⁿ   Phipps, Maureen G ^o   Silverstein, Michael ^p   Simon, Melissa A ^q   Tseng, Chien Wen ^r,s  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d STANFORD UNIVERSITY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f Columbia University ^*  (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

ⁱ NATIONWIDE CHILDREN S HOSPITAL   (United States)

^j Fairfax Family Practice Residency   (United States)

^k VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^l YALE UNIVERSITY   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o BROWN UNIVERSITY   (United States)

^p BOSTON UNIVERSITY   (United States)

^q NORTHWESTERN UNIVERSITY   (United States)

^r UNIVERSITY OF HAWAII   (United States)

^s PACIFIC HEALTH RESEARCH AND EDUCATION INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER MORTALITY; CANCER SCREENING; CANCER SURGERY; CAUSE OF DEATH; CLINICAL EVALUATION; DIAGNOSTIC ACCURACY; DISEASE BURDEN; FALSE POSITIVE RESULT; FEMALE; HEREDITARY TUMOR SYNDROME; HIGH RISK POPULATION; HUMAN; MORBIDITY; OUTCOME ASSESSMENT; OVARY CANCER; POSTOPERATIVE COMPLICATION; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PROGRAM EFFECTIVENESS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCREENING TEST; SYSTEMATIC REVIEW; UNITED STATES; ASYMPTOMATIC DISEASE; EARLY CANCER DIAGNOSIS; MASS SCREENING; MORTALITY; OVARY TUMOR; PRACTICE GUIDELINE; RISK FACTOR;

ASYMPTOMATIC DISEASES; EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MASS SCREENING; OVARIAN NEOPLASMS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS;

EID: 85042030671     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.21926     Document Type: Review

References (26)

1. US Cancer StatisticsWorking Group. United States Cancer Statistics (USCS): 1999-2014 cancer incidence and mortality data. https://nccd.cdc.gov /uscs/. 2017. Accessed December 19, 2017.
2. National Cancer Institute. Cancer Stat Facts: Ovarian cancer. https://seer.cancer.gov/statfacts /html/ovary.html. 2017. Accessed December 19, 2017.
3. Henderson JT, Webber EM, Sawaya GF. Screening for Ovarian Cancer: An Evidence Review for the US Preventive Services Task Force: Evidence Synthesis No. 157. Rockville, MD: Agency for Healthcare Research and Quality; 2018. AHRQ publication 17-05231-EF-1.
4. Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: An evidence review for the US Preventive Services Task Force. JAMA. doi:10.1001/jama.2017.21421
5. National Academies of Sciences, Engineering, and Medicine. Ovarian Cancers: Evolving Paradigms in Research and Care.Washington, DC: National Academies Press; 2016.
6. Stormo AR, Cooper CP, Hawkins NA, SaraiyaM. Physician characteristics and beliefs associated with use of pelvic examinations in asymptomatic women. Prev Med. 2012;54(6):415-421.
7. Bibbins-Domingo K, Grossman DC, Curry SJ, et al; US Preventive Services Task Force. Screening for gynecologic conditions with pelvic examination: US Preventive Services Task Force recommendation statement. JAMA. 2017;317(9): 947-953.
8. Buys SS, Partridge E, Black A, et al; PLCO Project Team. Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295-2303.
9. Doroudi M, Kramer BS, Pinsky PF. The bimanual ovarian palpation examination in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: Performance and complications. J Med Screen. 2017;24(4):220-222.
10. Moyer VA; U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(4):271-281.
11. National Cancer Institute. Genetics of Breast and Gynecologic Cancers (PDQ®)-health professional version. https://www.cancer.gov/types /breast/hp/breast-ovarian-genetics-pdq. 2017. Accessed December 20, 2017.
12. American Cancer Society. Cancer facts & figures 2017. https://www.cancer.org/research/cancer -facts-statistics/all-cancer-facts-figures/cancer -facts-figures-2017.html. 2017. Accessed December 19, 2017.
13. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291(22):2705-2712.
14. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review (CSR) 1975-2014. https://seer.cancer.gov/csr/1975-2014/. 2017. Accessed December 19, 2017.
15. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet. 2016;387(10022):945-956.
16. Protocol for the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Version 7.1. https://www.ucl.ac.uk/womens-health /research/womens-cancer/gynaecological-cancer -research-centre/ukctocs/files/ukctocs-protocol71. 2015. Accessed December 19, 2017.
17. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: A pilot randomised controlled trial. Lancet. 1999;353(9160):1207-1210.
18. Pinsky PF, Yu K, Kramer BS, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up. Gynecol Oncol. 2016;143(2):270-275.
19. Andersen MR, Drescher CW, Zheng Y, et al. Changes in cancer worry associated with participation in ovarian cancer screening. Psychooncology. 2007;16(9):814-820.
20. Barrett J, Jenkins V, Farewell V, et al; UKCTOCS Trialists. Psychological morbidity associated with ovarian cancer screening: Results from more than 23, 000 women in the randomised trial of ovarian cancer screening (UKCTOCS). BJOG. 2014;121(9): 1071-1079.
21. Moyer VA; U.S. Preventive Services Task Force. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2012;157(12):900-904.
22. Committee on Gynecologic Practice, Society of Gynecologic Oncology. Committee Opinion No. 716: The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk. Obstet Gynecol. 2017;130(3):e146-e149.
23. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2017;67(2):100-121.
24. Brown DL, Andreotti RF, Lee SI, et al. ACR appropriateness criteria© ovarian cancer screening. Ultrasound Q. 2010;26(4):219-223.
25. American Academy of Family Physicians. Clinical Preventive Service Recommendation: Ovarian cancer. https://www.aafp.org/patient-care /clinical-recommendations/all/ovarian-cancer.html. 2017. Accessed December 19, 2017.
26. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version I. FortWashington, PA: NCCN; 2017.